These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study. Huhle G, Hoffmann U, Hoffmann I, Liebe V, Harenberg JF, Heene DL. Thromb Res; 2000 Aug 15; 99(4):325-34. PubMed ID: 10963783 [Abstract] [Full Text] [Related]
5. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. Koster A, Hansen R, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F. J Cardiothorac Vasc Anesth; 2000 Jun 15; 14(3):243-8. PubMed ID: 10890473 [Abstract] [Full Text] [Related]
8. [Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin]. Marx A, Huhle G, Hoffmann U, Wang LC, Schüle B, Jani L, Harenberg J. Z Orthop Ihre Grenzgeb; 1999 Jun 15; 137(6):536-9. PubMed ID: 10666863 [Abstract] [Full Text] [Related]
9. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers. Esslinger HU, Haas S, Maurer R, Lassmann A, Dübbers K, Müller-Peltzer H. Thromb Haemost; 1997 May 15; 77(5):911-9. PubMed ID: 9184402 [Abstract] [Full Text] [Related]
11. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry R, Close P. Thromb Haemost; 1994 Aug 15; 72(2):227-31. PubMed ID: 7831657 [Abstract] [Full Text] [Related]
15. Treatment of an acute flush reaction caused by subcutaneous r-hirudin with pegylated hirudin. Harenberg J, Hoffmann U, Huhle G, Song XH, Wang LC. Br J Haematol; 2000 Mar 15; 108(3):528-30. PubMed ID: 10759710 [Abstract] [Full Text] [Related]
16. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Théroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A. Eur Heart J; 2000 Sep 15; 21(17):1473-81. PubMed ID: 10952840 [Abstract] [Full Text] [Related]
17. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time. Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G. Thromb Haemost; 1997 May 15; 77(5):920-5. PubMed ID: 9184403 [Abstract] [Full Text] [Related]
18. [Heparin induced thrombocytopenia type II after the use of low-molecular weight heparin. Case report and review of the literature]. Franke J, Schaeper O, Kayser R, Mahlfeld K. Unfallchirurg; 2003 Jan 15; 106(1):77-81. PubMed ID: 12552397 [Abstract] [Full Text] [Related]